PDCD1 and neoplasm: In this immunogenic model, where early treatment with anti-PD1 alone confers therapeutic benefit (Fig. 9A), treatment of orthotopic tumor–bearing mice with MRTX alone led to complete responses in 28% of the mice (Fig. 9B).